Prime Medicine, Inc. PRME
3.89 USD -0.41 (-9.53%)
At closeNov 12, 2026, 7:49 PM EST
3.94 +0.05 +1.29%
After hours · Nov 12, 7:49 PM ET
3.73 Day range 4.13
2.67 52-week range 5.91
- YTD
- +12.10%
- 1 year
- +9.58%
News
zacks.com Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.32 per share a year ago.
benzinga.com Prime Medicine Q3 EPS $(0.22) Beats $(0.25) Estimate, Sales $4.213M Beat $1.206M Estimate Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 31.25 percent increase over losses of $(0.32)…
globenewswire.com Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
globenewswire.com Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates -- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected…
247wallst.com Cathie Wood Dumps the Last of Teradyne From Her Flagship Fund ARK's flagship fund exited a chip-testing stock just as it surged on a fresh Buy rating, and Wood offered no explanation. Another ARK fund still holds millions in shares, so the real question is what…
globenewswire.com Prime Medicine Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
benzinga.com Prime Medicine Commences $125M Offering Of Common Shares Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an…
globenewswire.com Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
globenewswire.com Prime Medicine to Present at Jefferies Global Healthcare Conference CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
zacks.com Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains? Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
businesswire.com Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate…
zacks.com Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
seekingalpha.com Leading Indicators For The October Breakout Cycle Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have…
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesday's regular session. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 151.31% to $1.0. The…
benzinga.com Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.
globenewswire.com Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q…
benzinga.com Prime Medicine Gets FDA Green Light for Gene Editing Study Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New…
benzinga.com Prime Medicine Gets FDA Green Light for Gene Editing Study The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
benzinga.com Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
benzinga.com Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and INLIF surged on revenue growth.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix…
benzinga.com FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency -- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a ---- Initial clinical data expected…
globenewswire.com Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency -- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
seekingalpha.com Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Prime Drink Group Provides Bi-Weekly MCTO Status Report MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14 and August 27, 2026,…
globenewswire.com Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
defenseworld.net BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission…
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.- benzinga.com BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9 BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
seekingalpha.com Prime Medicine: Soon In The Clinic Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and…
benzinga.com HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
zacks.com Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.- benzinga.com Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of…
benzinga.com Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027 -- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a ---- PM577a targets the H1069Q mutation in the ATP7B gene, the most…
benzinga.com Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
benzinga.com Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX- benzinga.com Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam -- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD ---- Prime Medicine owes no monetary…
benzinga.com Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On Monday Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: QuidelOrtho, FuelCell, Ouster, Viasat, Swarmer, Charter, Prime Medicine, Roblox, Satellogic, Churchill…
benzinga.com This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.- benzinga.com HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
- benzinga.com Prime Medicine Says FDA Grants Regenerative Medicine Advanced Therapy Designation To PM359, Investigational Autologous Prime Edited Hematopoietic Stem Cell Therapy For Treatment Of p47phox-deficient CGD -- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in…
- benzinga.com Prime Medicine Receives New Zealand's Regulator Clearance For Its Clinical Trial Application For PM577a To Treat Wilson Disease Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the New Zealand Medicines…
benzinga.com Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
benzinga.com Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40)…- benzinga.com Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11 Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
- benzinga.com LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6 LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
benzinga.com Prime Medicine Announced New England Journal Of Medicine Publication Of PM359 Clinical Data For Two Patients For Treatment Of Chronic Granulomatous Disease Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2…- benzinga.com Citigroup Maintains Neutral on Prime Medicine, Lowers Price Target to $4.25 Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $5 to $4.25.